PLAG1 rearrangement may be an oncogenic driver in a subset of sporadic cardiac myxomas: a case–control study
-
By
-
Fausto Maffini
-
Daniela Lepanto
-
Eleonora Pisa
-
Eisa De Camilli
-
Valentina Catto
-
Chiara Zanetti
-
Simona Pessina
-
Corrado Carbucicchio
-
Fabio Pagni
-
Nicola Fusco
-
May 20, 2026
-
Clinical Scorecard: PLAG1 Rearrangements as Potential Oncogenic Factors in Certain Sporadic Cardiac Myxomas: Insights from a Case-Control Analysis
At a Glance
| Category | Detail |
|---|
| Condition | Sporadic Cardiac Myxoma (SCM) |
| Key Mechanisms | PLAG1 rearrangements and absence of MYC amplification |
| Target Population | Patients with sporadic cardiac myxoma |
| Care Setting | Cardiology and oncology departments |
Key Highlights
- PLAG1 rearrangements detected in 35.7% of SCM cases
- No MYC amplification observed in any SCM cases
- Study suggests potential molecular similarities with other tumors with myxoid stroma
- Histological features consistent with typical SCM morphology
- Findings warrant further investigation into cardiac myxoid tumors
Guideline-Based Recommendations
Diagnosis
- Use fluorescence in situ hybridization (FISH) to assess PLAG1 rearrangement
Management
- Monitor for typical SCM morphology and absence of malignancy
Monitoring & Follow-up
- Regular follow-up for potential recurrence or new tumor formation
Risks
- Consider genetic counseling for familial syndromes like Carney complex
Patient & Prescribing Data
Patients diagnosed with sporadic cardiac myxoma
Surgical resection is the primary treatment; genetic profiling may provide additional insights
Clinical Best Practices
- Incorporate genetic testing for PLAG1 rearrangements in SCM diagnosis
- Utilize histological and immunohistochemical analyses for accurate diagnosis
- Engage in multidisciplinary discussions for complex cases
Related Resources & Content
